|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001554,
umls-concept:C0010825,
umls-concept:C0017066,
umls-concept:C0029216,
umls-concept:C0030705,
umls-concept:C0031327,
umls-concept:C0032659,
umls-concept:C0348016,
umls-concept:C0440790,
umls-concept:C0442027,
umls-concept:C0524930,
umls-concept:C0909381
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2009-10-19
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
A population pharmacokinetics analysis was performed after intravenous ganciclovir and oral valganciclovir in solid organ transplant patients with cytomegalovirus. Patients received ganciclovir at 5 mg/kg of body weight (5 days) and then 900 mg of valganciclovir (16 days), both twice daily with dose adjustment for renal function. A total of 382 serum concentrations from days 5 and 15 were analyzed with NONMEM VI. Renal function given by creatinine clearance (CL(CR)) was the most influential covariate in CL. The final pharmacokinetic parameters were as follows: ganciclovir clearance (CL) was 7.49.(CL(CR)/57) liter/h (57 was the mean population value of CL(CR)); the central and peripheral distribution volumes were 31.9 liters and 32.0 liters, respectively; intercompartmental clearance was 10.2 liter/h; the first-order absorption rate constant was 0.895 h(-1); bioavailability was 0.825; and lag time was 0.382 h. The CL(CR) was the best predictor of CL, making dose adjustment by this covariate important to achieve the most efficacious ganciclovir exposure.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/19738014-10195646,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19738014-10496303,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19738014-10991864,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19738014-11465876,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19738014-12189361,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19738014-12228824,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19738014-1244564,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19738014-12476798,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19738014-14748816,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19738014-15819597,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19738014-15871635,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19738014-15940035,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19738014-16023764,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19738014-16352807,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19738014-16737936,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19738014-17571070,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19738014-17640310,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19738014-17653836,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19738014-17697259,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19738014-8138894,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19738014-8619596,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19738014-8786764,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19738014-8786955,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19738014-9795882
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1098-6596
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
53
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4816-24
|
|
pubmed:dateRevised |
2010-9-27
|
|
pubmed:meshHeading |
pubmed-meshheading:19738014-Administration, Oral,
pubmed-meshheading:19738014-Adult,
pubmed-meshheading:19738014-Aged,
pubmed-meshheading:19738014-Antiviral Agents,
pubmed-meshheading:19738014-Area Under Curve,
pubmed-meshheading:19738014-Cytomegalovirus Infections,
pubmed-meshheading:19738014-Female,
pubmed-meshheading:19738014-Ganciclovir,
pubmed-meshheading:19738014-Humans,
pubmed-meshheading:19738014-Injections, Intravenous,
pubmed-meshheading:19738014-Male,
pubmed-meshheading:19738014-Metabolic Clearance Rate,
pubmed-meshheading:19738014-Middle Aged,
pubmed-meshheading:19738014-Models, Biological,
pubmed-meshheading:19738014-Organ Transplantation,
pubmed-meshheading:19738014-Prospective Studies
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus.
|
|
pubmed:affiliation |
Nephrology Service, Hospital Universitari de Bellvitge, Barcelona, Spain.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
